[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2021091164A1 - Phamaceutical composition for preventing or treating obesity or allergy comprising rose extract as active ingredient - Google Patents

Phamaceutical composition for preventing or treating obesity or allergy comprising rose extract as active ingredient Download PDF

Info

Publication number
WO2021091164A1
WO2021091164A1 PCT/KR2020/014909 KR2020014909W WO2021091164A1 WO 2021091164 A1 WO2021091164 A1 WO 2021091164A1 KR 2020014909 W KR2020014909 W KR 2020014909W WO 2021091164 A1 WO2021091164 A1 WO 2021091164A1
Authority
WO
WIPO (PCT)
Prior art keywords
rose
rose extract
extract
preventing
obesity
Prior art date
Application number
PCT/KR2020/014909
Other languages
French (fr)
Korean (ko)
Inventor
김윤배
최은경
Original Assignee
충북대학교 산학협력단
주식회사 디자인셀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 충북대학교 산학협력단, 주식회사 디자인셀 filed Critical 충북대학교 산학협력단
Publication of WO2021091164A1 publication Critical patent/WO2021091164A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss

Definitions

  • the present invention relates to a pharmaceutical composition for the prevention or treatment of obesity or allergy containing a rose extract as an active ingredient.
  • Obesity is a state in which adipose tissue is excessively accumulated in the body, and it is defined as obesity when the body weight is divided by the square of the height (BMI) is 25 or more, which is an ester of fatty acids and glucose introduced into adipocytes from plasma. It is converted and accumulated in the body mainly in the form of triglycerides.
  • BMI height
  • obesity is caused by an energy imbalance that results from excessive intake of nutrients relative to energy expenditure over a long period of time.
  • obesity is one of the biggest causes of metabolic diseases such as hypertension, diabetes, dyslipidemia, and arteriosclerosis.
  • obesity inhibitors include satiety stimulating agents, liposuction inhibitors, antipsychotic appetite suppressants, and the like, among these drugs, antipsychotic appetite suppressants are classified as narcotics and may cause serious side effects. In addition, other drugs also cause serious side effects, so there is a problem that they are banned from sale or cannot be taken for a long time.
  • atopic dermatitis occurs at a rate of 10 to 20% in infants and 1 to 3% in adults, and the prevalence is steadily increasing.
  • type I allergy is a reaction involving IgE antibodies, and is also called anaphylaxis type allergy, and includes bronchial asthma, atopic disease, allergic rhinitis, allergic conjunctivitis, and the like.
  • Drugs used in the treatment of allergies are classified into degranulation inhibitors, chemical transporter inhibitors, and chemical transporter synthesis inhibitors, depending on their mechanism of action.
  • the action point of the drug is relatively certain, but the mechanism of action of the degranulation inhibitor is unclear, and there is a problem that these drugs may cause various side effects by long-term administration.
  • Korean Patent Publication No. 10-2019-0123384 discloses the use of eleokafucin for treating allergic diseases, which inhibits histamine release and degranulation of mast cells, and inhibits the expression of inflammatory cytokines.
  • the present invention provides a pharmaceutical composition for preventing or treating obesity comprising a rose extract as an active ingredient.
  • the present invention provides a health functional food for preventing or improving obesity comprising a rose extract as an active ingredient.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of allergy comprising a rose extract as an active ingredient.
  • the present invention provides a health functional food for the prevention or improvement of allergy comprising a rose extract as an active ingredient.
  • the present invention provides a method for preventing, improving or treating obesity, comprising administering a rose extract to an individual.
  • the present invention provides a use of a rose extract for use in the manufacture of a medicament for the prevention or treatment of obesity.
  • the present invention provides a method for preventing, improving or treating allergies comprising administering a rose extract to an individual.
  • the present invention provides a use of a rose extract for use in the manufacture of a medicament for the prevention or treatment of allergies.
  • the rose extract of the present invention inhibits adipogenesis in all fat cells, maintains the physical strength of the mouse in mice induced with dietary obesity by a high fat diet, while suppressing weight gain, production of abdominal adipose tissue and fatty liver, and acute allergic reactions.
  • the rose extract can be usefully used in the treatment of obesity or allergic diseases.
  • FIG. 1 is a view showing a photograph (A) and a graph (B) of a result of quantifying fat amount as a result of observing with an optical microscope after staining with oil red O of a rose extract for suppressing adipocyte production.
  • FIG. 2 is a graph showing the results of suppressing weight gain in a dietary obesity mouse model rose extract.
  • FIG. 3 is a diagram showing a photograph (A) and a graph (B) of a result of quantifying the amount of abdominal fat obtained by MRI photographing that rose extract suppresses abdominal fat in a dietary obesity mouse model.
  • Figure 4 is a graph showing the results confirming that rose extract inhibits the increase of adipose tissue in adipose tissue (A) or abdominal adipose tissue (B) around the epididymis of a dietary obesity mouse model.
  • FIG. 5 is a view showing a photograph (A) and a graph (B) of a result of measuring the size of adipocytes as a result of observing with an optical microscope that rose extract inhibits an increase in adipocyte size in a dietary obese mouse model.
  • Figure 6 is a diagram showing the results confirming that the rose extract inhibits the formation of fatty liver in a dietary obesity mouse model.
  • the present invention provides a pharmaceutical composition for preventing or treating obesity comprising a rose extract as an active ingredient.
  • the rose may include any plant known as a rose in the art.
  • the rose is a vine rose ( Rosa multiflora ), laurel flower ( Rosa cinensis ), musk rose ( Rosa moschata ), glycolysis flower (Rosa regosa ), damask rose ( Rosa damascena ), Poetida rose (Rosa foetida ), woodhyang It may be any one or more selected from the group consisting of rose ( Rosa banksiae) and their improved species. In one embodiment of the present invention, the rose may be a vine rose.
  • the rose extract may be extracted from any one or more selected from the group consisting of rose petals, stems, leaves, calyxes, and buds, and specifically any one selected from the group consisting of rose petals, calyxes, and buds. It may be extracted from the above. In one embodiment of the present invention, the rose extract may be extracted from a flower bud.
  • the rose extract can be prepared by a manufacturing method comprising the following steps:
  • step 3 drying the filtered filtrate of step 2) after concentrating under reduced pressure.
  • the extraction solvent may be water, alcohol, or a mixture thereof.
  • the alcohol may be a C 1 to C 2 lower alcohol, and specifically, the alcohol may be ethanol, methanol or alcohol.
  • the extraction solvent may be added in an amount of 3 to 30 times, 3 to 25 times, 3 to 20 times, 7 to 30 times, 7 to 25 times, 7 to 20 times the weight of the dried rose.
  • the extraction method may be shaking extraction, cold needle extraction, or reflux extraction. At this time, the extraction time may be 5 to 30 hours, 7 to 30 hours, 5 to 20 hours, 7 to 20 hours, 5 to 15 hours, 7 to 15 hours. The extraction may be repeated one or more times.
  • the vacuum concentration in step 3) may be performed using a vacuum vacuum concentrator or a vacuum rotary evaporator.
  • the drying may be vacuum drying, vacuum drying, boiling drying, spray drying, or freeze drying, and specifically, freeze drying.
  • the pharmaceutical composition according to the present invention may contain 10 to 95% by weight of rose extract, which is an active ingredient, based on the total weight of the composition.
  • the pharmaceutical composition of the present invention may further include one or more active ingredients exhibiting the same or similar functions in addition to the active ingredients.
  • the pharmaceutical composition of the present invention may contain a carrier, a diluent, an excipient, or a mixture thereof commonly used in biological preparations.
  • Any pharmaceutically acceptable carrier may be used as long as it is suitable for delivering the composition in vivo.
  • the carrier is Merck Index, 13th ed., Merck & Co. Inc., saline, sterile water, Ringer's solution, dextrose solution, maltodextrin solution, glycerol, ethanol, or a mixture thereof.
  • conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as needed.
  • diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants may be added.
  • the composition of the present invention may be formulated as an oral or parenteral formulation.
  • Oral formulations may include solid formulations and liquid formulations.
  • the solid preparation may be a tablet, a pill, a powder, a granule, a capsule or a troche, and the solid preparation may be prepared by adding at least one excipient to the composition.
  • the excipient may be starch, calcium carbonate, sucrose, lactose, gelatin, or a mixture thereof.
  • the solid preparation may contain a lubricant, and examples thereof include magnesium stearate and talc.
  • the liquid formulation may be a suspension, an inner solution, an emulsion or a syrup. At this time, the liquid formulation may contain excipients such as wetting agents, sweetening agents, fragrances, and preservatives.
  • the parenteral preparation may include injections, suppositories, powders for respiratory inhalation, aerosols for sprays, powders and creams.
  • the injection may include a sterilized aqueous solution, a non-aqueous solvent, a suspension solvent, an emulsion, and the like.
  • the non-aqueous solvent or suspension solvent vegetable oils such as propylene glycol, polyethylene glycol, and olive oil, or injectable esters such as ethyl oleate may be used.
  • the present invention provides a health functional food for preventing or improving obesity comprising a rose extract as an active ingredient.
  • the rose extract contained as an active ingredient in the health functional food according to the present invention may have the above-described characteristics.
  • the rose extract may be extracted from any one or more roses selected from the group consisting of vine rose, laurel flower, musk rose, glycolysis rose, damask rose, poetida rose, wood rose, and improved species thereof.
  • the rose extract may be extracted from any one or more selected from the group consisting of rose petals, stems, leaves, calyxes, and buds.
  • the rose extract may be extracted with water, C 1 to C 2 lower alcohol or a mixture thereof, and in this case, the C 1 to C 2 lower alcohol may be ethanol, methanol or alcohol.
  • the rose extract of the present invention may be added to food as it is, or may be used with other foods or food ingredients.
  • the content of the active ingredient to be added may be determined according to the purpose, and generally may be 0.01 to 90 parts by weight of the total food weight.
  • the form and type of the health functional food is not particularly limited.
  • the health functional food may be in the form of tablets, capsules, powders, granules, liquids, and pills.
  • the health functional food may contain various flavoring agents, sweetening agents, or natural carbohydrates as additional ingredients.
  • the sweetener may be a natural or synthetic sweetener, and examples of the natural sweetener include taumatin and stevia extract. Meanwhile, examples of synthetic sweeteners include saccharin and aspartame.
  • the natural carbohydrates may be monosaccharides, disaccharides, polysaccharides, oligosaccharides and sugar alcohols.
  • the health functional food of the present invention includes nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pexane and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives. , Glycerin, alcohol, and the like may be further included. These ingredients can be used independently or in combination.
  • the ratio of the additive may be selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of allergy comprising a rose extract as an active ingredient.
  • the rose extract contained as an active ingredient in the pharmaceutical composition according to the present invention may have the above-described characteristics.
  • the rose extract may be extracted from any one or more roses selected from the group consisting of vine rose, laurel flower, musk rose, glycolysis rose, damask rose, poetida rose, wood rose, and improved species thereof.
  • the rose extract may be extracted from any one or more selected from the group consisting of rose petals, stems, leaves, calyxes, and buds.
  • the rose extract may be extracted with water, C 1 to C 2 lower alcohol or a mixture thereof, and in this case, the C 1 to C 2 lower alcohol may be ethanol, methanol or alcohol.
  • the allergy may include all known allergies in the art. Specifically, the allergy may be a type I, II, III or IV allergy. In one embodiment of the present invention, the allergy may be a systemic shock reaction or skin itching caused by an acute allergy.
  • the pharmaceutical composition may have the characteristics as described above.
  • the present invention provides a health functional food for the prevention or improvement of allergies comprising a rose extract as an active ingredient.
  • the rose extract contained as an active ingredient in the health functional food according to the present invention may have the above-described characteristics.
  • the rose extract may be extracted from any one or more roses selected from the group consisting of vine rose, laurel flower, musk rose, glycolysis rose, damask rose, poetida rose, wood rose, and improved species thereof.
  • the rose extract may be extracted from any one or more selected from the group consisting of rose petals, stems, leaves, calyxes, and buds.
  • the rose extract may be extracted with water, C 1 to C 2 lower alcohol or a mixture thereof, and in this case, the C 1 to C 2 lower alcohol may be ethanol, methanol or alcohol.
  • the allergy may include all known allergies in the art. Specifically, the allergy may be a type I, II, III or IV allergy. In one embodiment of the present invention, the allergy may be a systemic shock reaction or skin itching caused by an acute allergy.
  • the health functional food may have the characteristics as described above.
  • the present invention provides a method for preventing, improving or treating obesity, comprising administering a rose extract to an individual.
  • the rose extract used in the method for preventing, improving or treating obesity according to the present invention may have the above-described characteristics.
  • the rose extract may be extracted from any one or more roses selected from the group consisting of vine rose, laurel flower, musk rose, glycolysis rose, damask rose, poetida rose, wood rose, and improved species thereof.
  • the rose extract may be extracted from any one or more selected from the group consisting of rose petals, stems, leaves, calyxes, and buds.
  • the rose extract may be extracted with water, C 1 to C 2 lower alcohol or a mixture thereof, and in this case, the C 1 to C 2 lower alcohol may be ethanol, methanol or alcohol.
  • the individual may be a mammal, and specifically, may be a human.
  • the administration may be administered orally or parenterally according to the desired method, and parenteral administration may be selected from external skin or intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection. I can.
  • the administration is administered in a pharmaceutically effective amount. This may vary depending on the type of disease, the severity, the activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and the rate of excretion, the treatment period, and the drugs used at the same time.
  • the RNA aptamer of the present invention may be administered alone or in combination with other therapeutic agents. When administered in combination, administration may be sequential or simultaneous.
  • the amount of the rose extract according to the present invention may be 0.001 to 10,000 mg/kg, specifically 0.1 g to 5 g/kg.
  • the administration may be once a day or may be divided into several times.
  • the present invention provides a use of a rose extract for use in the manufacture of a medicament for the prevention or treatment of obesity.
  • the rose extract used in the manufacture of a medicament for the prevention or treatment of obesity may have the characteristics as described above.
  • the rose extract may be extracted from any one or more roses selected from the group consisting of vine rose, laurel flower, musk rose, glycolysis rose, damask rose, poetida rose, wood rose, and improved species thereof.
  • the rose extract may be extracted from any one or more selected from the group consisting of rose petals, stems, leaves, calyxes, and buds.
  • the rose extract may be extracted with water, C 1 to C 2 lower alcohol or a mixture thereof, and in this case, the C 1 to C 2 lower alcohol may be ethanol, methanol or alcohol.
  • the present invention provides a method for preventing, improving or treating allergies comprising administering a rose extract to an individual.
  • the rose extract used in the method for preventing, improving or treating allergies according to the present invention may have the above-described characteristics.
  • the rose extract may be extracted from any one or more roses selected from the group consisting of vine rose, laurel flower, musk rose, glycolysis rose, damask rose, poetida rose, wood rose, and improved species thereof.
  • the rose extract may be extracted from any one or more selected from the group consisting of rose petals, stems, leaves, calyxes, and buds.
  • the rose extract may be extracted with water, C 1 to C 2 lower alcohol or a mixture thereof, and in this case, the C 1 to C 2 lower alcohol may be ethanol, methanol or alcohol.
  • the allergy may include all known allergies in the art. Specifically, the allergy may be a type I, II, III or IV allergy. In one embodiment of the present invention, the allergy may be a systemic shock reaction or skin itching caused by an acute allergy.
  • the individual may be a mammal, and specifically, may be a human.
  • the administration may have the characteristics as described above.
  • the present invention provides a use of a rose extract for use in the manufacture of a medicament for the prevention or treatment of allergies.
  • the rose extract used in the manufacture of a medicament for the prevention or treatment of allergies according to the present invention may have the above-described characteristics.
  • the rose extract may be extracted from any one or more roses selected from the group consisting of vine rose, laurel flower, musk rose, glycolysis rose, damask rose, poetida rose, wood rose, and improved species thereof.
  • the rose extract may be extracted from any one or more selected from the group consisting of rose petals, stems, leaves, calyxes, and buds.
  • the rose extract may be extracted with water, C 1 to C 2 lower alcohol or a mixture thereof, and in this case, the C 1 to C 2 lower alcohol may be ethanol, methanol or alcohol.
  • the allergy may include all known allergies in the art. Specifically, the allergy may be a type I, II, III or IV allergy. In one embodiment of the present invention, the allergy may be a systemic shock reaction or skin itching caused by an acute allergy.
  • the buds of the red vine rose (Rosa multiflora ) grown in an environment-friendly manner were collected and dried with hot air for 15 hours in a dryer at 65°C.
  • An alcohol equivalent to 10 times the weight of the dried vine rose bud was added, followed by reflux extraction at 85 ⁇ 5° C. for 10 to 12 hours.
  • the obtained extract was first filtered through a sieve of 100 mesh, and then filtered again using a sieve having a pore size of 50 ⁇ m or less.
  • the obtained filtrate was concentrated under reduced pressure at 65 ⁇ 5°C, sterilized at 85 ⁇ 5°C for 10 minutes, and then freeze-dried to obtain a rose extract.
  • a 3T3-L1 cell line which is a proliferative cell, was prepared by culturing in a conventional manner.
  • the prepared cells were dispensed into a 96-well plate at 1 ⁇ 10 6 cells per well, and the rose extract obtained in Example 1 was treated to be 30 or 100 ⁇ g/ml.
  • the 3T3-L1 cell line was differentiated and matured for 2 days using 5 ⁇ g/ml of insulin.
  • a buffer solution containing 7% formaldehyde was added to the mature cells, and the cells were fixed for 1 hour, and then 99% isopropanol containing 1% Oil Red O dye was added and stained for 10 minutes.
  • the triglycerides in the stained cells were observed using an optical microscope, and the photographed results are shown in FIG. 1A.
  • the amount of fat produced in the cells was quantified by measuring the oil red O eluted by treatment with isopropanol using an adipogenesis kit at 490 nm absorbance. The quantitative results are shown in Fig. 1B.
  • the amount of fat increased in 3T3-L1 cells by insulin was reduced by rose extract. From this, it was found that the rose extract inhibits intracellular adipogenesis.
  • the obesity improvement effect of the obtained rose extract was confirmed using a mouse model in which dietary obesity was induced.
  • mice 6-week-old male C57BL/6 mice were divided into 4 groups: a normal diet group, a high fat diet group, a 100 mg/kg rose extract administration group, and a 300 mg/kg rose extract administration group.
  • the prepared mice were fed and bred for 28 days.
  • rose extract was administered orally once a day while feeding a high-fat diet to the rose extract administration group.
  • Fig. 2 shows the results of measuring the weight change of the mice during the breeding period
  • Fig. 3 shows the results of confirming the accumulation of abdominal fat by photographing the abdomen by MRI.
  • mice of the high fat diet group significantly increased their body weight compared to the normal diet group, whereas such weight gain was suppressed by administration of rose extract.
  • mice of Experimental Example 2-1 were sacrificed, and the adipose tissue around the epididymis and the abdominal (mesentery) adipose tissue were removed, and the weight was measured to confirm the change of the adipose tissue by the rose extract.
  • the measurement results of the adipose tissue of the epididymis are shown in Fig. 4A, and the measurement results of the abdominal fat tissue are shown in Fig. 4B.
  • the adipose tissue around the epididymis increased by about 0.5 times and the abdominal adipose tissue by about 2.5 times by the high fat diet, and there was no significant change in the adipose tissue around the epididymis by the administration of rose extract (FIG. 4A). ), the abdominal adipose tissue was significantly reduced (Fig. 4B).
  • Hematoxylin-eosin staining was performed to confirm whether the decrease in abdominal adipose tissue identified in Experimental Example 2-2 was due to a decrease in the size of adipocytes.
  • adipose tissue was obtained from the sacrificed mouse of Experimental Example 2-1 by a conventional method, and a paraffin tissue slide was prepared. After staining the tissue by adding hematoxylin-eosin dye, the adipose tissue was observed using an optical microscope.
  • Fig. 5A shows a picture of adipose tissue taken with an optical microscope
  • Fig. 5B shows an average value obtained by measuring the size of adipocytes from the results using an image analyzer.
  • the size of adipocytes increased by more than two times by a high fat diet, but this increase was significantly suppressed by administration of rose extract.
  • mice of Experimental Example 2-1 were sacrificed to extract liver tissue, and the results of confirming the presence of fatty liver by observing with a microscope are shown in FIG. 6.
  • rose extract can be used to treat obesity caused by a high fat diet.
  • the rose extract administration group did not exhibit side effects such as decrease in physical strength due to the administration of the rose extract by swimming for a longer period of time compared to the normal diet group or the high fat diet group.
  • mice were intraperitoneally administered the rose extract prepared in Example 1 at a dose of 30, 100 or 300 mg/kg, and after 10 minutes, a compound promoting histamine release from mast cells 48/80 (compound 48/80) was administered intraperitoneally at a dose of 8 mg/kg.
  • a negative control mice to which only a solvent was administered instead of rose extract was used.
  • the mortality rate of mice due to systemic shock reaction for 1 hour was recorded in Table 1 below.
  • Administration group Death rate Negative control 10/10 (100%) 30 mg/kg administration group 4/10 (40%) 100 mg/kg administration group 1/10 (10%) 300 mg/kg administration group 0/10 (0%)
  • the rose extract prepared in Example 1 was administered intraperitoneally to a 7-week-old female ICR mouse at a dose of 100 or 300 mg/kg. After 30 minutes, mice and the like were depilated, and 50 ⁇ l of Compound 48/80 was injected subcutaneously in one place.
  • Fig. 8 shows the results of recording the number of times the mouse scratches the itchy area for 30 minutes after injection using its hind paws (scratching behaviors).
  • mice administered compound 48/80 scratched the itchy area 78 times on average, thereby showing severe itching, but it was confirmed that the number of scratches was significantly reduced in the mice administered with the rose extract.
  • the rose extract can be usefully used in the treatment of allergies by suppressing systemic shock reactions or local skin itching caused by acute allergic reactions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating obesity or an allergy, comprising a rose extract as an active ingredient. Specifically, the rose extract inhibits adipogenesis in all adipocytes, and suppresses weight gain, production of abdominal adipose tissue, and fatty liver in a mouse while maintaining the physical strength of the mouse, the mouse having been induced with dietary obesity by a high fat diet, and relieves a systemic shock reaction or skin itching caused by an acute allergic reaction, such that the rose extract can be effectively utilized in treating obesity or allergic diseases.

Description

장미 추출물을 유효성분으로 함유하는 비만 또는 알레르기의 예방 또는 치료용 약학적 조성물Pharmaceutical composition for preventing or treating obesity or allergy containing rose extract as an active ingredient
본 발명은 장미 추출물을 유효성분으로 함유하는 비만 또는 알레르기의 예방 또는 치료용 약학적 조성물에 관한 것이다.The present invention relates to a pharmaceutical composition for the prevention or treatment of obesity or allergy containing a rose extract as an active ingredient.
비만은 체내에 지방조직이 과다하게 축적된 상태로서, 체중을 신장의 제곱으로 나눈 값인 신체비만지수(BMI)가 25 이상일 경우 비만으로 정의하는데, 이는 혈장으로부터 지방세포로 유입된 지방산과 포도당이 에스테르화하여 주로 중성지방의 형태로 체내에 축적된다. 일반적으로 비만은 오랜 기간에 걸쳐 에너지 소비량에 비해 영양소를 과다 섭취하는 경우에 오는 에너지 불균형에서 유발된다. 또한, 비만은 고혈압, 당뇨, 이상고지혈증, 동맥경화 등과 같은 대사성 질환을 유발하는 가장 큰 원인 중 하나이다.Obesity is a state in which adipose tissue is excessively accumulated in the body, and it is defined as obesity when the body weight is divided by the square of the height (BMI) is 25 or more, which is an ester of fatty acids and glucose introduced into adipocytes from plasma. It is converted and accumulated in the body mainly in the form of triglycerides. In general, obesity is caused by an energy imbalance that results from excessive intake of nutrients relative to energy expenditure over a long period of time. In addition, obesity is one of the biggest causes of metabolic diseases such as hypertension, diabetes, dyslipidemia, and arteriosclerosis.
국가 통계포털에 따르면 2018년을 기준으로 만 19세 이상의 비만 유병률은 42.8%였고, 이중 남성은 51.4%, 여성은 25.5%로 확인되었다. 2007년부터 전체적으로 비만 유병률이 증가하는 추세에 있으며 특히 여성에 비해 남성의 비만 유병률이 급증하였다. 이와 같이, 비만 인구뿐만 아니라, 비만으로 인한 합병증 환자 발생률 또한 증가하고 있어, 전 세계적으로 비만 인구 및 관련 질환자의 수가 급증하고 있다.According to the national statistics portal, as of 2018, the prevalence of obesity over the age of 19 was 42.8%, of which 51.4% were male and 25.5% were female. Since 2007, the overall prevalence of obesity has been on the rise, especially in men compared to women. As described above, not only the obese population but also the incidence of complications due to obesity is increasing, and the number of obese population and related diseases is rapidly increasing worldwide.
비만을 더 이상 단순한 과체중이 아닌 하나의 치료가 필요한 질환으로 인식하기 시작하면서 2013년에 WHO는 비만을 새로운 전염병으로 명시하였다. 이에, 선진국에서는 일찍이 비만 예방제 또는 치료제를 개발하기 위한 연구 및 투자가 활발히 이루어지고 있다. 이러한 노력으로 현재 전 세계에는 비만을 억제하기 위한 수백개의 비만 억제제가 개발 및 시판되었으며, 국내에서도 60여종의 비만 억제제가 판매되고 있다. 이와 같은, 비만 억제제는 포만감 항진제, 지방흡수억제제 또는 항정신성 식욕억제제 등을 포함하는데, 이들 약물 중에서 항정신성 식욕억제제는 마약류로 분류되고 있으며 심각한 부작용을 유발할 수 있어 사용에 주의가 필요하다. 이외에도 다른 약물들 또한 심각한 부작용을 유발하여 판매가 금지되거나 장기간 복용할 수 없다는 문제가 있다.In 2013, the WHO identified obesity as a new epidemic, as obesity was no longer just overweight, but as a disease that needed treatment. Accordingly, research and investment to develop obesity preventive or therapeutic agents are being actively conducted in developed countries. With these efforts, hundreds of obesity inhibitors have been developed and marketed to suppress obesity all over the world, and over 60 types of obesity inhibitors are being sold in Korea. Such obesity inhibitors include satiety stimulating agents, liposuction inhibitors, antipsychotic appetite suppressants, and the like, among these drugs, antipsychotic appetite suppressants are classified as narcotics and may cause serious side effects. In addition, other drugs also cause serious side effects, so there is a problem that they are banned from sale or cannot be taken for a long time.
한편, 최근 현대인들은 집먼지 진드기, 황사, 미세먼지, 애완동물의 털, 꽃가루, 식품첨가물 등과 같이 면역 과민반응을 유발하는 다양한 알레르기원(allergen)에 노출되는 기회가 증가하면서, 그에 따라 알레르기 환자의 수도 증가하고 있는 추세이다. 특히, 아토피 피부염은 영유아에서 10 내지 20%, 성인에서 1 내지 3%의 비율로 발병하고 있으며, 유병율이 꾸준히 증가하고 있다.On the other hand, modern people are increasingly exposed to various allergens that cause immune hypersensitivity reactions, such as house dust mites, yellow dust, fine dust, pet hair, pollen, and food additives. It is an increasing trend. In particular, atopic dermatitis occurs at a rate of 10 to 20% in infants and 1 to 3% in adults, and the prevalence is steadily increasing.
알레르기는 면역기전에 따라, I, II, III 및 IV형으로 분류되며, I, II 및 III형 알레르기는 즉시형 알레르기로, IV형 알레르기는 지연형 알레르기로 분류된다. 이중, I형 알레르기는 IgE 항체가 관여하는 반응으로, 아나필락시형 알레르기라고도 불리며 기관지 천식, 아토피성 질환, 알레르기성 비염, 알레르기성 결막염 등이 포함된다.Allergies are classified into types I, II, III and IV according to the immune mechanism, type I, II and III allergies are classified as immediate type allergies, and type IV allergies are classified as delayed type allergies. Among them, type I allergy is a reaction involving IgE antibodies, and is also called anaphylaxis type allergy, and includes bronchial asthma, atopic disease, allergic rhinitis, allergic conjunctivitis, and the like.
알레르기의 치료에 사용되는 약물은 작용 기전에 따라 탈과립 저해제, 화학전달물질 작용억제제, 화학전달물질 합성저해제 등으로 분류된다. 화학전달물질 작용억제제와 화학전달물질 합성저해제의 경우 약물 작용점이 비교적 확실하지만, 탈과립 저해제의 경우 그 작용기전이 불분명하며, 또한 이들 약물들은 장기간 투여에 의해 여러 부작용을 초래할 수 있다는 문제가 있다. 이와 관련하여, 대한민국 특허공개 제10-2019-0123384호는 비만세포의 히스타민 방출 및 탈과립을 억제하고, 염증성 사이토카인의 발현을 억제하는 엘레오카푸신의 알레르기 질환 치료 용도를 개시하고 있다.Drugs used in the treatment of allergies are classified into degranulation inhibitors, chemical transporter inhibitors, and chemical transporter synthesis inhibitors, depending on their mechanism of action. In the case of chemical transport agent inhibitors and chemical transport agent synthesis inhibitors, the action point of the drug is relatively certain, but the mechanism of action of the degranulation inhibitor is unclear, and there is a problem that these drugs may cause various side effects by long-term administration. In this regard, Korean Patent Publication No. 10-2019-0123384 discloses the use of eleokafucin for treating allergic diseases, which inhibits histamine release and degranulation of mast cells, and inhibits the expression of inflammatory cytokines.
본 발명의 목적은 장미 추출물의 비만 또는 알레르기 치료용 조성물을 제공하는 것이다.It is an object of the present invention to provide a composition for treating obesity or allergies of rose extract.
상기 목적을 달성하기 위하여, 본 발명은 장미 추출물을 유효성분으로 포함하는 비만의 예방 또는 치료용 약학적 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating obesity comprising a rose extract as an active ingredient.
또한, 본 발명은 장미 추출물을 유효성분으로 포함하는 비만의 예방 또는 개선용 건강기능식품을 제공한다.In addition, the present invention provides a health functional food for preventing or improving obesity comprising a rose extract as an active ingredient.
또한, 본 발명은 장미 추출물을 유효성분으로 포함하는 알레르기의 예방 또는 치료용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of allergy comprising a rose extract as an active ingredient.
또한, 본 발명은 장미 추출물을 유효성분으로 포함하는 알레르기의 예방 또는 개선용 건강기능식품을 제공한다.In addition, the present invention provides a health functional food for the prevention or improvement of allergy comprising a rose extract as an active ingredient.
또한, 본 발명은 장미 추출물을 개체에 투여하는 단계를 포함하는 비만의 예방, 개선 또는 치료방법을 제공한다.In addition, the present invention provides a method for preventing, improving or treating obesity, comprising administering a rose extract to an individual.
또한, 본 발명은 비만의 예방 또는 치료를 위한 약제의 제조에 사용하기 위한 장미 추출물의 용도를 제공한다.In addition, the present invention provides a use of a rose extract for use in the manufacture of a medicament for the prevention or treatment of obesity.
또한, 본 발명은 장미 추출물을 개체에 투여하는 단계를 포함하는 알레르기의 예방, 개선 또는 치료방법을 제공한다.In addition, the present invention provides a method for preventing, improving or treating allergies comprising administering a rose extract to an individual.
나아가, 본 발명은 알레르기의 예방 또는 치료를 위한 약제의 제조에 사용하기 위한 장미 추출물의 용도를 제공한다.Furthermore, the present invention provides a use of a rose extract for use in the manufacture of a medicament for the prevention or treatment of allergies.
본 발명의 장미 추출물은 전지방세포에서 지방생성을 억제하고, 고지방식이로 식이성 비만이 유도된 마우스에서 마우스의 체력을 유지시키면서 체중증가, 복부지방조직 생성 및 지방간을 억제하며, 급성 알레르기 반응에 의한 전신성 쇼크반응이나 피부 가려움증을 완화함으로써, 상기 장미 추출물은 비만 또는 알레르기 질환의 치료에 유용하게 사용될 수 있다.The rose extract of the present invention inhibits adipogenesis in all fat cells, maintains the physical strength of the mouse in mice induced with dietary obesity by a high fat diet, while suppressing weight gain, production of abdominal adipose tissue and fatty liver, and acute allergic reactions. By alleviating systemic shock reactions or skin itching caused by, the rose extract can be usefully used in the treatment of obesity or allergic diseases.
도 1은 장미 추출물의 지방세포 생성 억제 효과를 오일 레드 O 염색하여 광학현미경을 이용해 관찰한 결과 사진(A) 및 지방량을 정량한 결과 그래프(B)를 나타내는 도면이다.1 is a view showing a photograph (A) and a graph (B) of a result of quantifying fat amount as a result of observing with an optical microscope after staining with oil red O of a rose extract for suppressing adipocyte production.
도 2는 장미 추출물이 식이성 비만 마우스 모델에서 체중 증가를 억제한 결과를 나타내는 그래프이다.2 is a graph showing the results of suppressing weight gain in a dietary obesity mouse model rose extract.
도 3은 장미 추출물이 식이성 비만 마우스 모델에서 복부 지방을 억제하는 것을 MRI 촬영한 결과 사진(A) 및 복부 지방량을 정량한 결과 그래프(B)를 나타내는 도면이다.FIG. 3 is a diagram showing a photograph (A) and a graph (B) of a result of quantifying the amount of abdominal fat obtained by MRI photographing that rose extract suppresses abdominal fat in a dietary obesity mouse model.
도 4는 장미 추출물이 식이성 비만 마우스 모델의 부고환 주위 지방조직(A) 또는 복부 지방조직(B)에서 지방조직의 증가를 억제하는 것을 확인한 결과 그래프이다.Figure 4 is a graph showing the results confirming that rose extract inhibits the increase of adipose tissue in adipose tissue (A) or abdominal adipose tissue (B) around the epididymis of a dietary obesity mouse model.
도 5는 장미 추출물이 식이성 비만 마우스 모델의 지방세포 크기 증가를 억제하는 것을 광학현미경을 이용해 관찰한 결과 사진(A) 및 지방세포의 크기를 측정한 결과 그래프(B)를 나타내는 도면이다.5 is a view showing a photograph (A) and a graph (B) of a result of measuring the size of adipocytes as a result of observing with an optical microscope that rose extract inhibits an increase in adipocyte size in a dietary obese mouse model.
도 6은 장미 추출물이 식이성 비만 마우스 모델에서 지방간 형성을 억제하는 것을 확인한 결과 도면이다.Figure 6 is a diagram showing the results confirming that the rose extract inhibits the formation of fatty liver in a dietary obesity mouse model.
도 7은 장미 추출물에 의한 마우스 동물모델의 체력 변화를 확인한 결과 그래프이다.7 is a graph showing the results of confirming the change in physical strength of the mouse animal model by rose extract.
도 8은 장미 추출물이 급성 알레르기 반응에 의한 피부 가려움증을 억제하는 것을 확인한 결과 그래프이다.8 is a graph showing the results confirming that the rose extract suppresses skin itching caused by an acute allergic reaction.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 장미 추출물을 유효성분으로 포함하는 비만의 예방 또는 치료용 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing or treating obesity comprising a rose extract as an active ingredient.
상기 장미는 통상의 기술분야에 장미로 알려진 식물이면 어떠한 것도 포함될 수 있다. 일례로, 상기 장미는 덩굴장미( Rosa multiflora), 월계화( Rosa cinensis), 사향장미( Rosa moschata), 해당화( Rosa regosa), 다마스크 장미( Rosa damascena), 포에티다 장미( Rosa foetida), 목향장미( Rosa banksiae) 및 이들의 개량종으로 구성된 군으로부터 선택되는 어느 하나 이상일 수 있다. 본 발명의 일 실시예에서, 상기 장미는 덩굴장미일 수 있다.The rose may include any plant known as a rose in the art. For example, the rose is a vine rose ( Rosa multiflora ), laurel flower ( Rosa cinensis ), musk rose ( Rosa moschata ), glycolysis flower (Rosa regosa ), damask rose ( Rosa damascena ), Poetida rose (Rosa foetida ), woodhyang It may be any one or more selected from the group consisting of rose ( Rosa banksiae) and their improved species. In one embodiment of the present invention, the rose may be a vine rose.
상기 장미 추출물은 장미의 꽃잎, 줄기, 잎, 꽃받침 및 꽃봉오리로 구성된 군으로부터 선택되는 어느 하나 이상으로부터 추출된 것일 수 있고, 구체적으로 장미의 꽃잎, 꽃받침 및 꽃봉오리로 구성된 군으로부터 선택되는 어느 하나 이상으로부터 추출된 것일 수 있다. 본 발명의 일 실시예에서, 상기 장미 추출물은 꽃봉오리로부터 추출된 것일 수 있다.The rose extract may be extracted from any one or more selected from the group consisting of rose petals, stems, leaves, calyxes, and buds, and specifically any one selected from the group consisting of rose petals, calyxes, and buds. It may be extracted from the above. In one embodiment of the present invention, the rose extract may be extracted from a flower bud.
상기 장미 추출물은 하기의 단계를 포함하는 제조방법에 의해 제조될 수 있다:The rose extract can be prepared by a manufacturing method comprising the following steps:
1) 장미에 추출용매를 가하여 추출물을 제조하는 단계;1) preparing an extract by adding an extraction solvent to the rose;
2) 단계 1)의 추출물을 여과하는 단계; 및2) filtering the extract of step 1); And
3) 단계 2)의 여과된 여과물을 감압농축한 후 건조하는 단계.3) drying the filtered filtrate of step 2) after concentrating under reduced pressure.
또한, 상기 추출용매는 물, 알코올 또는 이의 혼합물일 수 있다. 상기 알코올은 C 1 내지 C 2의 저급 알코올 수 있고, 구체적으로, 상기 알코올은 에탄올, 메탄올 또는 주정일 수 있다. 상기 추출용매는 건조된 장미 무게의 3 내지 30배, 3 내지 25배, 3 내지 20배, 7 내지 30배, 7 내지 25배, 7 내지 20배로 첨가될 수 있다.In addition, the extraction solvent may be water, alcohol, or a mixture thereof. The alcohol may be a C 1 to C 2 lower alcohol, and specifically, the alcohol may be ethanol, methanol or alcohol. The extraction solvent may be added in an amount of 3 to 30 times, 3 to 25 times, 3 to 20 times, 7 to 30 times, 7 to 25 times, 7 to 20 times the weight of the dried rose.
상기 추출방법은 진탕추출, 냉침추출 또는 환류추출일 수 있다. 이때, 추출 시간은 5 내지 30시간, 7 내지 30시간, 5 내지 20시간, 7 내지 20시간, 5 내지 15시간, 7 내지 15시간일 수 있다. 상기 추출은 1회 이상 반복 추출할 수 있다.The extraction method may be shaking extraction, cold needle extraction, or reflux extraction. At this time, the extraction time may be 5 to 30 hours, 7 to 30 hours, 5 to 20 hours, 7 to 20 hours, 5 to 15 hours, 7 to 15 hours. The extraction may be repeated one or more times.
한편, 상기 단계 3)의 감압농축은 진공감압농축기 또는 진공회전증발기를 이용할 수 있다. 또한, 상기 건조는 감압건조, 진공건조, 비등건조, 분무건조 또는 동결건조일 수 있고, 구체적으로는 동결건조일 수 있다.Meanwhile, the vacuum concentration in step 3) may be performed using a vacuum vacuum concentrator or a vacuum rotary evaporator. In addition, the drying may be vacuum drying, vacuum drying, boiling drying, spray drying, or freeze drying, and specifically, freeze drying.
본 발명에 따른 약학적 조성물은 조성물 전체 중량에 대하여 유효성분인 장미 추출물을 10 내지 95 중량%로 포함할 수 있다. 또한, 본 발명의 약학적 조성물은 상기 유효성분 이외에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 추가로 포함할 수 있다.The pharmaceutical composition according to the present invention may contain 10 to 95% by weight of rose extract, which is an active ingredient, based on the total weight of the composition. In addition, the pharmaceutical composition of the present invention may further include one or more active ingredients exhibiting the same or similar functions in addition to the active ingredients.
본 발명의 약학적 조성물은 생물학적 제제에 통상적으로 사용되는 담체, 희석제, 부형제 또는 이의 혼합물을 포함할 수 있다. 약학적으로 허용가능한 담체는 조성물을 생체 내에 전달하는데 적합한 것이면 모두 사용할 수 있다. 구체적으로, 상기 담체는 Merck Index, 13th ed., Merck & Co. Inc.에 기재된 화합물, 식염수, 멸균수, 링거액, 덱스트로스 용액, 말토덱스트린 용액, 글리세롤, 에탄올 또는 이의 혼합물일 수 있다. 또한, 필요에 따라 항산화제, 완충액, 정균제 등과 같은 통상의 첨가제를 첨가할 수 있다.The pharmaceutical composition of the present invention may contain a carrier, a diluent, an excipient, or a mixture thereof commonly used in biological preparations. Any pharmaceutically acceptable carrier may be used as long as it is suitable for delivering the composition in vivo. Specifically, the carrier is Merck Index, 13th ed., Merck & Co. Inc., saline, sterile water, Ringer's solution, dextrose solution, maltodextrin solution, glycerol, ethanol, or a mixture thereof. In addition, conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as needed.
상기 조성물을 제제화하는 경우, 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 첨가할 수 있다.When formulating the composition, diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants may be added.
본 발명의 조성물은 경구용 제제 또는 비경구용 제제로 제형화될 수 있다. 경구용 제제로는 고형 제제 및 액상 제제가 포함될 수 있다. 상기 고형 제제는 정제, 환제, 산제, 과립제, 캡슐제 또는 트로키제일 수 있고, 이러한 고형 제제는 상기 조성물에 적어도 하나 이상의 부형제를 첨가하여 조제할 수 있다. 상기 부형제는 전분, 탄산칼슘, 수크로스, 락토오스, 젤라틴 또는 이의 혼합물일 수 있다. 또한, 상기 고형 제제는 윤활제를 포함할 수 있고, 그 예로는 마그네슘 스티레이트, 탈크등이 있다. 한편, 상기 액상 제제는 현탁제, 내용액제, 유제 또는 시럽제일 수 있다. 이때, 상기 액상 제제에는 습윤제, 감미제, 방향제, 보존제 등과 같은 부형제가 포함될 수 있다.The composition of the present invention may be formulated as an oral or parenteral formulation. Oral formulations may include solid formulations and liquid formulations. The solid preparation may be a tablet, a pill, a powder, a granule, a capsule or a troche, and the solid preparation may be prepared by adding at least one excipient to the composition. The excipient may be starch, calcium carbonate, sucrose, lactose, gelatin, or a mixture thereof. In addition, the solid preparation may contain a lubricant, and examples thereof include magnesium stearate and talc. On the other hand, the liquid formulation may be a suspension, an inner solution, an emulsion or a syrup. At this time, the liquid formulation may contain excipients such as wetting agents, sweetening agents, fragrances, and preservatives.
상기 비경구용 제제는 주사제, 좌제, 호흡기 흡입용 분말, 스프레이용 에어로졸제, 파우더 및 크림 등을 포함할 수 있다. 상기 주사제는 멸균된 수용액, 비수성용제, 현탁용제, 유제 등을 포함할 수 있다. 이때, 비수성용제 또는 현탁용제로서는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 기름이나, 에틸올레이트와 같이 주사가능한 에스테르 등이 사용될 수 있다.The parenteral preparation may include injections, suppositories, powders for respiratory inhalation, aerosols for sprays, powders and creams. The injection may include a sterilized aqueous solution, a non-aqueous solvent, a suspension solvent, an emulsion, and the like. At this time, as the non-aqueous solvent or suspension solvent, vegetable oils such as propylene glycol, polyethylene glycol, and olive oil, or injectable esters such as ethyl oleate may be used.
또한, 본 발명은 장미 추출물을 유효성분으로 포함하는 비만의 예방 또는 개선용 건강기능식품을 제공한다.In addition, the present invention provides a health functional food for preventing or improving obesity comprising a rose extract as an active ingredient.
본 발명에 따른 건강기능식품에 유효성분으로 포함되는 장미 추출물은 상술한 바와 같은 특징을 가질 수 있다. 일례로, 상기 장미 추출물은 덩굴장미, 월계화, 사향장미, 해당화, 다마스크 장미, 포에티다 장미, 목향장미 및 이들의 개량종으로 구성된 군으로부터 선택되는 어느 하나 이상의 장미로부터 추출된 것일 수 있다. 또한, 상기 장미 추출물은 장미의 꽃잎, 줄기, 잎, 꽃받침 및 꽃봉오리로 구성된 군으로부터 선택되는 어느 하나 이상으로부터 추출된 것일 수 있다.The rose extract contained as an active ingredient in the health functional food according to the present invention may have the above-described characteristics. As an example, the rose extract may be extracted from any one or more roses selected from the group consisting of vine rose, laurel flower, musk rose, glycolysis rose, damask rose, poetida rose, wood rose, and improved species thereof. In addition, the rose extract may be extracted from any one or more selected from the group consisting of rose petals, stems, leaves, calyxes, and buds.
상기 장미 추출물은 물, C 1 내지 C 2의 저급 알코올 또는 이의 혼합물로 추출된 것일 수 있고, 이때, C 1 내지 C 2의 저급 알코올은 에탄올, 메탄올 또는 주정일 수 있다.The rose extract may be extracted with water, C 1 to C 2 lower alcohol or a mixture thereof, and in this case, the C 1 to C 2 lower alcohol may be ethanol, methanol or alcohol.
본 발명의 장미 추출물은 식품에 그대로 첨가하거나, 다른 식품 또는 식품 성분과 함께 사용될 수 있다. 이때, 첨가되는 유효성분의 함량은 목적에 따라 결정될 수 있고, 일반적으로는 전체 식품 중량의 0.01 내지 90 중량부일 수 있다.The rose extract of the present invention may be added to food as it is, or may be used with other foods or food ingredients. At this time, the content of the active ingredient to be added may be determined according to the purpose, and generally may be 0.01 to 90 parts by weight of the total food weight.
건강기능식품의 형태 및 종류는 특별히 제한되지 않는다. 구체적으로, 상기 건강기능식품은 정제, 캅셀, 분말, 과립, 액상 및 환의 형태일 수 있다. 상기 건강기능식품은 추가성분으로서 여러 가지 향미제, 감미제 또는 천연 탄수화물을 포함할 수 있다. 상기 감미제는 천연 또는 합성 감미제일 수 있고, 천연 감미제의 예로는 타우마틴, 스테비아 추출물 등이 있다. 한편, 합성 감미제의 예로는 사카린, 아스파르탐 등이 있다. 또한, 상기 천연 탄수화물은 모노사카라이드, 디사카라이드, 폴리사카라이드, 올리고당 및 당알코올 등일 수 있다.The form and type of the health functional food is not particularly limited. Specifically, the health functional food may be in the form of tablets, capsules, powders, granules, liquids, and pills. The health functional food may contain various flavoring agents, sweetening agents, or natural carbohydrates as additional ingredients. The sweetener may be a natural or synthetic sweetener, and examples of the natural sweetener include taumatin and stevia extract. Meanwhile, examples of synthetic sweeteners include saccharin and aspartame. In addition, the natural carbohydrates may be monosaccharides, disaccharides, polysaccharides, oligosaccharides and sugar alcohols.
본 발명의 건강기능식품은 상기 서술한 추가성분 외에, 영양제, 비타민, 전해질, 풍미제, 착색제, 펙스탄 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올 등을 더 포함할 수 있다. 이러한 성분은 독립적으로 또는 조합으로 사용될 수 있다. 상기 첨가제의 비율은 본 발명의 조성물의 100 중량부당 0.01 내지 0.1 중량부의 범위에서 선택될 수 있다.In addition to the above-described additional ingredients, the health functional food of the present invention includes nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pexane and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives. , Glycerin, alcohol, and the like may be further included. These ingredients can be used independently or in combination. The ratio of the additive may be selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
또한, 본 발명은 장미 추출물을 유효성분으로 포함하는 알레르기의 예방 또는 치료용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of allergy comprising a rose extract as an active ingredient.
본 발명에 따른 약학적 조성물에 유효성분으로 포함되는 장미 추출물은 상술한 바와 같은 특징을 가질 수 있다. 일례로, 상기 장미 추출물은 덩굴장미, 월계화, 사향장미, 해당화, 다마스크 장미, 포에티다 장미, 목향장미 및 이들의 개량종으로 구성된 군으로부터 선택되는 어느 하나 이상의 장미로부터 추출된 것일 수 있다. 또한, 상기 장미 추출물은 장미의 꽃잎, 줄기, 잎, 꽃받침 및 꽃봉오리로 구성된 군으로부터 선택되는 어느 하나 이상으로부터 추출된 것일 수 있다.The rose extract contained as an active ingredient in the pharmaceutical composition according to the present invention may have the above-described characteristics. As an example, the rose extract may be extracted from any one or more roses selected from the group consisting of vine rose, laurel flower, musk rose, glycolysis rose, damask rose, poetida rose, wood rose, and improved species thereof. In addition, the rose extract may be extracted from any one or more selected from the group consisting of rose petals, stems, leaves, calyxes, and buds.
상기 장미 추출물은 물, C 1 내지 C 2의 저급 알코올 또는 이의 혼합물로 추출된 것일 수 있고, 이때, C 1 내지 C 2의 저급 알코올은 에탄올, 메탄올 또는 주정일 수 있다.The rose extract may be extracted with water, C 1 to C 2 lower alcohol or a mixture thereof, and in this case, the C 1 to C 2 lower alcohol may be ethanol, methanol or alcohol.
상기 알레르기는 통상의 기술분야에 알레르기라고 알려진 것을 모두 포함할 수 있다. 구체적으로, 상기 알레르기는 I, II, III 또는 IV형 알레르기일 수 있다. 본 발명의 일 실시예에서, 상기 알레르기는 급성 알레르기에 의해 유발되는 전신성 쇼크반응 또는 피부 가려움증일 수 있다.The allergy may include all known allergies in the art. Specifically, the allergy may be a type I, II, III or IV allergy. In one embodiment of the present invention, the allergy may be a systemic shock reaction or skin itching caused by an acute allergy.
또한, 상기 약학적 조성물은 상술한 바와 같은 특징을 가질 수 있다.In addition, the pharmaceutical composition may have the characteristics as described above.
나아가, 본 발명은 장미 추출물을 유효성분으로 포함하는 알레르기의 예방 또는 개선용 건강기능식품을 제공한다.Furthermore, the present invention provides a health functional food for the prevention or improvement of allergies comprising a rose extract as an active ingredient.
본 발명에 따른 건강기능식품에 유효성분으로 포함되는 장미 추출물은 상술한 바와 같은 특징을 가질 수 있다. 일례로, 상기 장미 추출물은 덩굴장미, 월계화, 사향장미, 해당화, 다마스크 장미, 포에티다 장미, 목향장미 및 이들의 개량종으로 구성된 군으로부터 선택되는 어느 하나 이상의 장미로부터 추출된 것일 수 있다. 또한, 상기 장미 추출물은 장미의 꽃잎, 줄기, 잎, 꽃받침 및 꽃봉오리로 구성된 군으로부터 선택되는 어느 하나 이상으로부터 추출된 것일 수 있다.The rose extract contained as an active ingredient in the health functional food according to the present invention may have the above-described characteristics. As an example, the rose extract may be extracted from any one or more roses selected from the group consisting of vine rose, laurel flower, musk rose, glycolysis rose, damask rose, poetida rose, wood rose, and improved species thereof. In addition, the rose extract may be extracted from any one or more selected from the group consisting of rose petals, stems, leaves, calyxes, and buds.
상기 장미 추출물은 물, C 1 내지 C 2의 저급 알코올 또는 이의 혼합물로 추출된 것일 수 있고, 이때, C 1 내지 C 2의 저급 알코올은 에탄올, 메탄올 또는 주정일 수 있다.The rose extract may be extracted with water, C 1 to C 2 lower alcohol or a mixture thereof, and in this case, the C 1 to C 2 lower alcohol may be ethanol, methanol or alcohol.
상기 알레르기는 통상의 기술분야에 알레르기라고 알려진 것을 모두 포함할 수 있다. 구체적으로, 상기 알레르기는 I, II, III 또는 IV형 알레르기일 수 있다. 본 발명의 일 실시예에서, 상기 알레르기는 급성 알레르기에 의해 유발되는 전신성 쇼크반응 또는 피부 가려움증일 수 있다.The allergy may include all known allergies in the art. Specifically, the allergy may be a type I, II, III or IV allergy. In one embodiment of the present invention, the allergy may be a systemic shock reaction or skin itching caused by an acute allergy.
또한, 상기 건강기능식품은 상술한 바와 같은 특징을 가질 수 있다.In addition, the health functional food may have the characteristics as described above.
또한, 본 발명은 장미 추출물을 개체에 투여하는 단계를 포함하는 비만의 예방, 개선 또는 치료방법을 제공한다.In addition, the present invention provides a method for preventing, improving or treating obesity, comprising administering a rose extract to an individual.
본 발명에 따른 비만의 예방, 개선 또는 치료방법에 사용되는 장미 추출물은 상술한 바와 같은 특징을 가질 수 있다. 일례로, 상기 장미 추출물은 덩굴장미, 월계화, 사향장미, 해당화, 다마스크 장미, 포에티다 장미, 목향장미 및 이들의 개량종으로 구성된 군으로부터 선택되는 어느 하나 이상의 장미로부터 추출된 것일 수 있다. 또한, 상기 장미 추출물은 장미의 꽃잎, 줄기, 잎, 꽃받침 및 꽃봉오리로 구성된 군으로부터 선택되는 어느 하나 이상으로부터 추출된 것일 수 있다.The rose extract used in the method for preventing, improving or treating obesity according to the present invention may have the above-described characteristics. As an example, the rose extract may be extracted from any one or more roses selected from the group consisting of vine rose, laurel flower, musk rose, glycolysis rose, damask rose, poetida rose, wood rose, and improved species thereof. In addition, the rose extract may be extracted from any one or more selected from the group consisting of rose petals, stems, leaves, calyxes, and buds.
상기 장미 추출물은 물, C 1 내지 C 2의 저급 알코올 또는 이의 혼합물로 추출된 것일 수 있고, 이때, C 1 내지 C 2의 저급 알코올은 에탄올, 메탄올 또는 주정일 수 있다.The rose extract may be extracted with water, C 1 to C 2 lower alcohol or a mixture thereof, and in this case, the C 1 to C 2 lower alcohol may be ethanol, methanol or alcohol.
상기 개체는 포유동물일 수 있고, 구체적으로 인간일 수 있다.The individual may be a mammal, and specifically, may be a human.
상기 투여는 목적하는 방법에 따라 경구 투여하거나 비경구 투여될수 있으며, 비경구 투여는 피부 외용 또는 복강내 주사, 직장내 주사, 피하주사, 정맥주사, 근육내 주사 또는 흉부내 주사 주입방식중 선택될 수 있다.The administration may be administered orally or parenterally according to the desired method, and parenteral administration may be selected from external skin or intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection. I can.
또한, 상기 투여는 약제학적으로 유효한 양으로 투여된다. 이는 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 동시 사용되는 약물 등에 따라 달라질 수 있다. 본 발명의 RNA 앱타머는 단독 또는 다른 치료제와 병용하여 투여될 수 있다. 병용 투여시, 투여는 순차적 또는 동시일 수 있다. In addition, the administration is administered in a pharmaceutically effective amount. This may vary depending on the type of disease, the severity, the activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and the rate of excretion, the treatment period, and the drugs used at the same time. The RNA aptamer of the present invention may be administered alone or in combination with other therapeutic agents. When administered in combination, administration may be sequential or simultaneous.
그러나, 바람직한 효과를 위해서, 본 발명에 따른 장미 추출물의 양은 0.001 ~ 10,000 mg/㎏, 구체적으로는 0.1 g ~ 5 g/kg 일 수 있다. 상기 투여는 하루에 1회일 수 있고, 수회로 나뉠 수도 있다.However, for a desirable effect, the amount of the rose extract according to the present invention may be 0.001 to 10,000 mg/kg, specifically 0.1 g to 5 g/kg. The administration may be once a day or may be divided into several times.
또한, 본 발명은 비만의 예방 또는 치료를 위한 약제의 제조에 사용하기 위한 장미 추출물의 용도를 제공한다.In addition, the present invention provides a use of a rose extract for use in the manufacture of a medicament for the prevention or treatment of obesity.
본 발명에 따른 비만의 예방 또는 치료를 위한 약제의 제조에 사용되는 장미 추출물은 상술한 바와 같은 특징을 가질 수 있다. 일례로, 상기 장미 추출물은 덩굴장미, 월계화, 사향장미, 해당화, 다마스크 장미, 포에티다 장미, 목향장미 및 이들의 개량종으로 구성된 군으로부터 선택되는 어느 하나 이상의 장미로부터 추출된 것일 수 있다. 또한, 상기 장미 추출물은 장미의 꽃잎, 줄기, 잎, 꽃받침 및 꽃봉오리로 구성된 군으로부터 선택되는 어느 하나 이상으로부터 추출된 것일 수 있다.The rose extract used in the manufacture of a medicament for the prevention or treatment of obesity according to the present invention may have the characteristics as described above. As an example, the rose extract may be extracted from any one or more roses selected from the group consisting of vine rose, laurel flower, musk rose, glycolysis rose, damask rose, poetida rose, wood rose, and improved species thereof. In addition, the rose extract may be extracted from any one or more selected from the group consisting of rose petals, stems, leaves, calyxes, and buds.
상기 장미 추출물은 물, C 1 내지 C 2의 저급 알코올 또는 이의 혼합물로 추출된 것일 수 있고, 이때, C 1 내지 C 2의 저급 알코올은 에탄올, 메탄올 또는 주정일 수 있다.The rose extract may be extracted with water, C 1 to C 2 lower alcohol or a mixture thereof, and in this case, the C 1 to C 2 lower alcohol may be ethanol, methanol or alcohol.
또한, 본 발명은 장미 추출물을 개체에 투여하는 단계를 포함하는 알레르기의 예방, 개선 또는 치료방법을 제공한다.In addition, the present invention provides a method for preventing, improving or treating allergies comprising administering a rose extract to an individual.
본 발명에 따른 알레르기의 예방, 개선 또는 치료방법에 사용되는 장미 추출물은 상술한 바와 같은 특징을 가질 수 있다. 일례로, 상기 장미 추출물은 덩굴장미, 월계화, 사향장미, 해당화, 다마스크 장미, 포에티다 장미, 목향장미 및 이들의 개량종으로 구성된 군으로부터 선택되는 어느 하나 이상의 장미로부터 추출된 것일 수 있다. 또한, 상기 장미 추출물은 장미의 꽃잎, 줄기, 잎, 꽃받침 및 꽃봉오리로 구성된 군으로부터 선택되는 어느 하나 이상으로부터 추출된 것일 수 있다.The rose extract used in the method for preventing, improving or treating allergies according to the present invention may have the above-described characteristics. As an example, the rose extract may be extracted from any one or more roses selected from the group consisting of vine rose, laurel flower, musk rose, glycolysis rose, damask rose, poetida rose, wood rose, and improved species thereof. In addition, the rose extract may be extracted from any one or more selected from the group consisting of rose petals, stems, leaves, calyxes, and buds.
상기 장미 추출물은 물, C 1 내지 C 2의 저급 알코올 또는 이의 혼합물로 추출된 것일 수 있고, 이때, C 1 내지 C 2의 저급 알코올은 에탄올, 메탄올 또는 주정일 수 있다.The rose extract may be extracted with water, C 1 to C 2 lower alcohol or a mixture thereof, and in this case, the C 1 to C 2 lower alcohol may be ethanol, methanol or alcohol.
상기 알레르기는 통상의 기술분야에 알레르기라고 알려진 것을 모두 포함할 수 있다. 구체적으로, 상기 알레르기는 I, II, III 또는 IV형 알레르기일 수 있다. 본 발명의 일 실시예에서, 상기 알레르기는 급성 알레르기에 의해 유발되는 전신성 쇼크반응 또는 피부 가려움증일 수 있다.The allergy may include all known allergies in the art. Specifically, the allergy may be a type I, II, III or IV allergy. In one embodiment of the present invention, the allergy may be a systemic shock reaction or skin itching caused by an acute allergy.
상기 개체는 포유동물일 수 있고, 구체적으로 인간일 수 있다. 또한, 상기 투여는 상술한 바와 같은 특징을 가질 수 있다.The individual may be a mammal, and specifically, may be a human. In addition, the administration may have the characteristics as described above.
나아가, 본 발명은 알레르기의 예방 또는 치료를 위한 약제의 제조에 사용하기 위한 장미 추출물의 용도를 제공한다.Furthermore, the present invention provides a use of a rose extract for use in the manufacture of a medicament for the prevention or treatment of allergies.
본 발명에 따른 알레르기의 예방 또는 치료를 위한 약제의 제조에 사용되는 장미 추출물은 상술한 바와 같은 특징을 가질 수 있다. 일례로, 상기 장미 추출물은 덩굴장미, 월계화, 사향장미, 해당화, 다마스크 장미, 포에티다 장미, 목향장미 및 이들의 개량종으로 구성된 군으로부터 선택되는 어느 하나 이상의 장미로부터 추출된 것일 수 있다. 또한, 상기 장미 추출물은 장미의 꽃잎, 줄기, 잎, 꽃받침 및 꽃봉오리로 구성된 군으로부터 선택되는 어느 하나 이상으로부터 추출된 것일 수 있다.The rose extract used in the manufacture of a medicament for the prevention or treatment of allergies according to the present invention may have the above-described characteristics. As an example, the rose extract may be extracted from any one or more roses selected from the group consisting of vine rose, laurel flower, musk rose, glycolysis rose, damask rose, poetida rose, wood rose, and improved species thereof. In addition, the rose extract may be extracted from any one or more selected from the group consisting of rose petals, stems, leaves, calyxes, and buds.
상기 장미 추출물은 물, C 1 내지 C 2의 저급 알코올 또는 이의 혼합물로 추출된 것일 수 있고, 이때, C 1 내지 C 2의 저급 알코올은 에탄올, 메탄올 또는 주정일 수 있다.The rose extract may be extracted with water, C 1 to C 2 lower alcohol or a mixture thereof, and in this case, the C 1 to C 2 lower alcohol may be ethanol, methanol or alcohol.
상기 알레르기는 통상의 기술분야에 알레르기라고 알려진 것을 모두 포함할 수 있다. 구체적으로, 상기 알레르기는 I, II, III 또는 IV형 알레르기일 수 있다. 본 발명의 일 실시예에서, 상기 알레르기는 급성 알레르기에 의해 유발되는 전신성 쇼크반응 또는 피부 가려움증일 수 있다.The allergy may include all known allergies in the art. Specifically, the allergy may be a type I, II, III or IV allergy. In one embodiment of the present invention, the allergy may be a systemic shock reaction or skin itching caused by an acute allergy.
이하, 본 발명을 하기 실시예에 의해 상세히 설명한다, 단, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐, 이들에 의해 본 발명이 제한되는 것은 아니다. 본 발명의 청구범위에 기재된 기술적 사상과 실질적으로 동일한 구성을 갖고 동일한 작용 효과를 이루는 것은 어떠한 것이라도 본 발명의 기술적 범위에 포함된다.Hereinafter, the present invention will be described in detail by the following examples, provided that the following examples are for illustrative purposes only, and the present invention is not limited thereto. Anything that has substantially the same configuration as the technical idea described in the claims of the present invention and achieves the same operation and effects is included in the technical scope of the present invention.
실시예 1. 장미 추출물의 제조Example 1. Preparation of rose extract
친환경으로 재배된 적색의 덩굴장미( Rosa multiflora)의 꽃봉오리를 채취하여 65℃의 건조기에서 15시간 동안 열풍건조하였다. 건조된 덩굴장미 꽃봉오리의 중량을 기준으로 10배에 해당하는 주정을 첨가하고, 85±5℃에서 10 내지 12시간 동안 환류추출하였다. 수득된 추출물을 100 메쉬(mesh)의 체를 이용하여 1차 여과하고, 이를 다시 50 ㎛ 이하의 포어(pore) 사이즈를 갖는 체를 이용하여 2차 여과하였다. 수득된 여과물을 65±5℃에서 감압농축하고, 85±5℃에서 10분 동안 살균한 후, 동결건조하여 장미 추출물을 수득하였다. The buds of the red vine rose (Rosa multiflora ) grown in an environment-friendly manner were collected and dried with hot air for 15 hours in a dryer at 65°C. An alcohol equivalent to 10 times the weight of the dried vine rose bud was added, followed by reflux extraction at 85±5° C. for 10 to 12 hours. The obtained extract was first filtered through a sieve of 100 mesh, and then filtered again using a sieve having a pore size of 50 μm or less. The obtained filtrate was concentrated under reduced pressure at 65±5°C, sterilized at 85±5°C for 10 minutes, and then freeze-dried to obtain a rose extract.
실험예 1. 장미 추출물의 지방생성 억제 효과 확인Experimental Example 1. Confirmation of the effect of inhibiting adipogenesis of rose extract
상기 수득된 장미 추출물의 지방생성 억제 효과를 오일 레드 O 염색 방법으로 확인하였다.The effect of inhibiting adipogenesis of the obtained rose extract was confirmed by the Oil Red O staining method.
먼저, 전지방세포인 3T3-L1 세포주를 통상적인 방법으로 배양하여 준비하였다. 준비된 세포를 96웰 플레이트에 웰당 1×10 6 cells이 되도록 분주하고, 실시예 1에서 수득된 장미 추출물을 30 또는 100 ㎍/㎖이 되도록 처리하였다. 여기에, 5 ㎍/㎖의 인슐린을 이용하여 2일 동안 3T3-L1 세포주를 분화 및 성숙시켰다. 성숙된 세포에 7% 포름알데하이드가 포함된 완충용액을 첨가하고 1시간 동안 세포를 고정한 뒤, 1% 오일 레드 O 염색약이 포함된 99%의 이소프로판올을 첨가하여 10분 동안 염색하였다. 염색된 세포 내 중성지방을 광학현미경을 이용하여 관찰하고, 이를 촬영한 결과를 도 1A에 나타내었다. 또한, 상기 세포 내에 생성된 지방량은 아디포제네시스 키트(adipogenesis kit)를 이용하여, 이소프로판올을 처리하여 용출된 오일 레드 O를 490 ㎚ 흡광도에서 측정함으로써 정량하였다. 정량 결과는 도 1B에 나타내었다.First, a 3T3-L1 cell line, which is a proliferative cell, was prepared by culturing in a conventional manner. The prepared cells were dispensed into a 96-well plate at 1×10 6 cells per well, and the rose extract obtained in Example 1 was treated to be 30 or 100 μg/ml. Here, the 3T3-L1 cell line was differentiated and matured for 2 days using 5 μg/ml of insulin. A buffer solution containing 7% formaldehyde was added to the mature cells, and the cells were fixed for 1 hour, and then 99% isopropanol containing 1% Oil Red O dye was added and stained for 10 minutes. The triglycerides in the stained cells were observed using an optical microscope, and the photographed results are shown in FIG. 1A. In addition, the amount of fat produced in the cells was quantified by measuring the oil red O eluted by treatment with isopropanol using an adipogenesis kit at 490 nm absorbance. The quantitative results are shown in Fig. 1B.
도 1에 나타낸 바와 같이, 인슐린에 의해 3T3-L1 세포 내에 증가된 지방량이 장미 추출물에 의해 감소되었다. 이로부터, 장미 추출물이 세포 내 지방생성을 억제함을 알 수 있었다.As shown in Fig. 1, the amount of fat increased in 3T3-L1 cells by insulin was reduced by rose extract. From this, it was found that the rose extract inhibits intracellular adipogenesis.
실험예 2. 장미 추출물의 비만 개선 효과 확인Experimental Example 2. Obesity improvement effect of rose extract confirmed
2-1. 체중변화 확인2-1. Check weight change
상기 수득된 장미 추출물의 비만 개선 효과를 식이성 비만이 유도된 마우스 모델을 이용하여 확인하였다.The obesity improvement effect of the obtained rose extract was confirmed using a mouse model in which dietary obesity was induced.
먼저, 6주령의 수컷 C57BL/6 마우스를 정상식이군, 고지방식이군, 100 ㎎/㎏의 장미 추출물 투여군 및 300 ㎎/㎏의 장미 추출물 투여군의 4개의 그룹으로 나누었다. 준비된 마우스에 28일 동안 사료를 급여하여 사육하였고, 이때, 장미 추출물 투여군에는 고지방식이 사료를 급여하면서 장미 추출물을 1일 1회 경구로 투여하였다. 사육기간 동안 마우스의 체중변화를 측정한 결과를 도 2에, 복부를 MRI로 촬영하여 복부지방 축적을 확인한 결과를 도 3에 나타내었다.First, 6-week-old male C57BL/6 mice were divided into 4 groups: a normal diet group, a high fat diet group, a 100 mg/kg rose extract administration group, and a 300 mg/kg rose extract administration group. The prepared mice were fed and bred for 28 days. At this time, rose extract was administered orally once a day while feeding a high-fat diet to the rose extract administration group. Fig. 2 shows the results of measuring the weight change of the mice during the breeding period, and Fig. 3 shows the results of confirming the accumulation of abdominal fat by photographing the abdomen by MRI.
도 2에 나타낸 바와 같이, 고지방식이군의 마우스는 정상식이군에 비해 체중이 유의적으로 증가한 반면, 이와 같은 체중 증가는 장미 추출물의 투여에 의해 억제되었다.As shown in FIG. 2, the mice of the high fat diet group significantly increased their body weight compared to the normal diet group, whereas such weight gain was suppressed by administration of rose extract.
또한, 도 3에 나타난 바와 같이, 고지방식이에 의해 축적된 마우스의 복부 지방이 장미 추출물 투여에 의해 억제되었다.In addition, as shown in Fig. 3, the abdominal fat of the mouse accumulated by the high fat diet was suppressed by the administration of rose extract.
2-2. 지방조직 변화 확인2-2. Confirmation of adipose tissue change
실험예 2-1의 마우스를 희생하여 부고환 주위 지방조직 및 복부(장간막) 지방조직을 적출하고 그 무게를 측정하여 장미 추출물에 의한 지방조직 변화를 확인하였다. 부고환 주의 지방조직의 측정 결과는 도 4A에, 복부 지방조직의 측정 결과는 도 4B에 나타내었다.The mice of Experimental Example 2-1 were sacrificed, and the adipose tissue around the epididymis and the abdominal (mesentery) adipose tissue were removed, and the weight was measured to confirm the change of the adipose tissue by the rose extract. The measurement results of the adipose tissue of the epididymis are shown in Fig. 4A, and the measurement results of the abdominal fat tissue are shown in Fig. 4B.
도 4에 나타난 바와 같이, 고지방식이에 의해 부고환 주위 지방조직은 약 0.5배, 복부 지방조직은 약 2.5배 증가하였고, 장미 추출물 투여에 의해 부고환 주위 지방조직은 유의적인 변화가 없었으나(도 4A), 복부 지방조직은 현저히 감소하였다(도 4B).As shown in Figure 4, the adipose tissue around the epididymis increased by about 0.5 times and the abdominal adipose tissue by about 2.5 times by the high fat diet, and there was no significant change in the adipose tissue around the epididymis by the administration of rose extract (FIG. 4A). ), the abdominal adipose tissue was significantly reduced (Fig. 4B).
2-3. 복부지방 감소의 원인 확인2-3. Identifying the cause of abdominal fat reduction
실험예 2-2에서 확인된 복부 지방조직의 감소가 지방세포 크기 감소에 의한 것인지 확인하기 위해 헤마톡실린-에오신(hematoxylin-eosin) 염색을 수행하였다.Hematoxylin-eosin staining was performed to confirm whether the decrease in abdominal adipose tissue identified in Experimental Example 2-2 was due to a decrease in the size of adipocytes.
먼저, 희생된 실험예 2-1의 마우스로부터 복부 지방조직을 통상적인 방법으로 수득하고, 파라핀조직 슬라이드를 제작하였다. 여기에 헤마톡실린-에오신 염색약을 첨가하여 조직을 염색한 후, 광학현미경을 이용하여 지방조직을 관찰하였다. 광학현미경으로 촬영한 지방조직의 사진을 도 5A에, 이미지 아날라이저(image analyzer)를 이용하여 상기 결과로부터 지방세포의 크기를 측정한 평균 값을 도 5B에 나타내었다.First, abdominal adipose tissue was obtained from the sacrificed mouse of Experimental Example 2-1 by a conventional method, and a paraffin tissue slide was prepared. After staining the tissue by adding hematoxylin-eosin dye, the adipose tissue was observed using an optical microscope. Fig. 5A shows a picture of adipose tissue taken with an optical microscope, and Fig. 5B shows an average value obtained by measuring the size of adipocytes from the results using an image analyzer.
도 5에 나타난 바와 같이, 고지방식이에 의해 지방세포의 크기가 2배 이상 증가하였으나, 이와 같은 증가는 장미 추출물의 투여에 의해 유의적으로 억제되었다.As shown in FIG. 5, the size of adipocytes increased by more than two times by a high fat diet, but this increase was significantly suppressed by administration of rose extract.
2-4. 지방간 현상 확인2-4. Checking the phenomenon of fatty liver
실험예 2-1의 마우스를 희생하여 간조직을 적출하고, 현미경으로 관찰하여 지방간 여부를 확인한 결과를 도 6에 나타내었다.The mice of Experimental Example 2-1 were sacrificed to extract liver tissue, and the results of confirming the presence of fatty liver by observing with a microscope are shown in FIG. 6.
도 6에 나타낸 바와 같이, 고지방식이에 의해 간조직에서 많은 수의 지방적이 관찰되었으나, 증가된 지방적은 장미 추출물의 투여에 의해 유의적으로 억제되었다.As shown in Fig. 6, a large number of fat masses were observed in liver tissue by a high fat diet, but the increased fat mass was significantly suppressed by administration of rose extract.
따라서, 상기 결과로부터 장미 추출물이 고지방식이에 의한 비만을 치료하는데 사용될 수 있음을 확인하였다.Therefore, it was confirmed from the above results that rose extract can be used to treat obesity caused by a high fat diet.
실험예 3. 장미 추출물에 의한 체력 변화 확인Experimental Example 3. Confirmation of changes in physical strength by rose extract
장미 추출물의 항비만 활성에 의해 개체의 체력이 변하는지 여부를 지구력 테스트를 수행함으로써 다음과 같이 확인하였다. 실험은 실시예 2-1의 마우스가 수조 안에서 수영하는 최대 시간을 측정함으로써 수행되었고, 측정된 시간은 도 7에 나타내었다.It was confirmed as follows by performing an endurance test whether the individual's physical strength is changed by the anti-obesity activity of the rose extract. The experiment was performed by measuring the maximum time that the mouse of Example 2-1 swims in the water tank, and the measured time is shown in FIG. 7.
도 7에 나타낸 바와 같이, 장미 추출물 투여군이 정상식이군이나 고지방식이군에 비해 더 긴 시간동안 수영을 함으로써, 장미 추출물 투여에 의해 체력이 감소하는 등의 부작용은 나타나지 않음을 확인하였다.As shown in FIG. 7, it was confirmed that the rose extract administration group did not exhibit side effects such as decrease in physical strength due to the administration of the rose extract by swimming for a longer period of time compared to the normal diet group or the high fat diet group.
실험예 4. 장미 추출물의 알레르기 개선 효과Experimental Example 4. Allergy improvement effect of rose extract
4-1. 전신성 쇼크반응 억제 효과 확인4-1. Confirmation of the effect of suppressing systemic shock reaction
장미 추출물이 급성 알레르기 반응에 의한 전신성 쇼크반응을 억제하는지를 다음과 같은 방법으로 확인하였다.It was confirmed by the following method whether rose extract inhibits systemic shock reactions caused by acute allergic reactions.
먼저, 7주령의 암컷 ICR 마우스에 실시예 1에서 제조된 장미 추출물을 30, 100 또는 300 ㎎/㎏의 용량으로 복강투여하고, 10분 후, 비만세포(mast cell)로부터 히스타민 유리를 촉진시키는 컴파운드 48/80(compound 48/80)을 8 ㎎/㎏의 용량으로 복강투여하였다. 이때, 음성 대조군으로 장미 추출물 대신 용매만을 투여한 마우스를 사용하였다. 투여 후, 1시간 동안 전신성 쇼크반응에 의한 마우스의 사망률을 하기 표 1에 기록하였다.First, a 7-week-old female ICR mouse was intraperitoneally administered the rose extract prepared in Example 1 at a dose of 30, 100 or 300 mg/kg, and after 10 minutes, a compound promoting histamine release from mast cells 48/80 (compound 48/80) was administered intraperitoneally at a dose of 8 mg/kg. At this time, as a negative control, mice to which only a solvent was administered instead of rose extract was used. After administration, the mortality rate of mice due to systemic shock reaction for 1 hour was recorded in Table 1 below.
투여군Administration group 사망율Death rate
음성 대조군 Negative control 10/10(100%)10/10 (100%)
30 ㎎/㎏ 투여군30 mg/kg administration group 4/10(40%)4/10 (40%)
100 ㎎/㎏ 투여군100 mg/kg administration group 1/10(10%)1/10 (10%)
300 ㎎/㎏ 투여군300 mg/kg administration group 0/10(0%)0/10 (0%)
표 1에 나타낸 바와 같이, 음성 대조군의 경우 10마리의 모든 마우스가 전신성 쇼크반응에 의해 사망하였으나, 장미 추출물 투여군은 투여된 장미 추출물의 농도에 의존적으로 마우스의 사망율이 감소하였다. 특히 300 ㎎/㎏의 장미 추출물을 투여한 군은 모든 마우스가 생존하여, 0%의 사망율을 나타내었다.As shown in Table 1, in the case of the negative control group, all 10 mice died due to systemic shock reaction, but in the rose extract-administered group, the mortality rate of the mice decreased depending on the concentration of the administered rose extract. In particular, in the group administered with 300 mg/kg of rose extract, all mice survived and showed a mortality rate of 0%.
4-2. 피부 가려움증 개선 확인4-2. Confirmation of improvement of skin itching
장미 추출물이 급성 알레르기 반응에 의한 피부 가려움증을 개선하는지를 다음과 같은 방법으로 확인하였다.It was confirmed by the following method whether rose extract improves skin itching caused by acute allergic reactions.
먼저, 7주령의 암컷 ICR 마우스에 실시예 1에서 제조된 장미 추출물을 100 또는 300 ㎎/㎏의 투여량으로 복강투여하였다. 30분 후, 마우스 등을 제모하여 50 ㎕의 컴파운드 48/80을 한 군데에 피하주사하였다. 주사 후, 30분 동안 마우스가 뒷발을 이용하여 가려운 부위를 긁는 횟수(scratching behaviors)를 기록한 결과를 도 8에 나타내었다.First, the rose extract prepared in Example 1 was administered intraperitoneally to a 7-week-old female ICR mouse at a dose of 100 or 300 mg/kg. After 30 minutes, mice and the like were depilated, and 50 µl of Compound 48/80 was injected subcutaneously in one place. Fig. 8 shows the results of recording the number of times the mouse scratches the itchy area for 30 minutes after injection using its hind paws (scratching behaviors).
도 8에 나타낸 바와 같이, 컴파운드 48/80을 투여한 마우스는 평균 78회 가려운 부위를 긁음으로써, 심한 가려움증을 나타내었으나, 장미 추출물을 투여한 마우스는 긁는 횟수가 현저히 감소함을 확인하였다.As shown in Figure 8, the mice administered compound 48/80 scratched the itchy area 78 times on average, thereby showing severe itching, but it was confirmed that the number of scratches was significantly reduced in the mice administered with the rose extract.
따라서, 상기로부터 장미 추출물은 급성 알레르기 반응에 의한 전신성 쇼크반응이나, 국소성 피부 가려움증을 억제함으로써, 알레르기 치료에 유용하게 사용될 수 있음을 확인하였다.Therefore, it was confirmed from the above that the rose extract can be usefully used in the treatment of allergies by suppressing systemic shock reactions or local skin itching caused by acute allergic reactions.

Claims (13)

  1. 장미 추출물을 유효성분으로 포함하는 비만의 예방 또는 치료용 약학적 조성물.A pharmaceutical composition for preventing or treating obesity, comprising a rose extract as an active ingredient.
  2. 제1항에 있어서, 상기 장미는 덩굴장미( Rosa multiflora), 월계화( Rosa cinensis), 사향장미( Rosa moschata), 해당화( Rosa regosa), 다마스크 장미( Rosa damascena), 포에티다 장미( Rosa foetida), 목향장미( Rosa banksiae) 및 이들의 개량종으로 구성된 군으로부터 선택되는 어느 하나 이상인, 비만의 예방 또는 치료용 약학적 조성물.The method of claim 1, wherein the rose is a vine rose ( Rosa multiflora ), a laurel flower ( Rosa cinensis ), a musk rose ( Rosa moschata ), a glycolysis flower (Rosa regosa ), a damask rose ( Rosa damascena ), and a poetida rose (Rosa foetida). ), Mokhyang rose (Rosa banksiae ) and any one or more selected from the group consisting of improved species thereof, a pharmaceutical composition for the prevention or treatment of obesity.
  3. 제1항에 있어서, 상기 장미는 장미의 꽃잎, 줄기, 잎, 꽃받침 및 꽃봉오리로 구성된 군으로부터 선택되는 어느 하나 이상인, 비만의 예방 또는 치료용 약학적 조성물.The pharmaceutical composition for preventing or treating obesity according to claim 1, wherein the rose is any one or more selected from the group consisting of rose petals, stems, leaves, calyxes, and buds.
  4. 제1항에 있어서, 상기 추출물이 물, C 1 내지 C 2의 저급 알코올 또는 이의 혼합물로 추출된, 비만의 예방 또는 치료용 약학적 조성물.The pharmaceutical composition for preventing or treating obesity according to claim 1, wherein the extract is extracted with water, C 1 to C 2 lower alcohol or a mixture thereof.
  5. 제4항에 있어서, 상기 C 1 내지 C 2의 저급 알코올이 에탄올, 메탄올 또는 주정인, 비만의 예방 또는 치료용 약학적 조성물.The pharmaceutical composition for preventing or treating obesity according to claim 4, wherein the C 1 to C 2 lower alcohol is ethanol, methanol or alcohol.
  6. 장미 추출물을 유효성분으로 포함하는 비만의 예방 또는 개선용 건강기능식품.Health functional food for preventing or improving obesity, containing rose extract as an active ingredient.
  7. 장미 추출물을 유효성분으로 포함하는 알레르기의 예방 또는 치료용 약학적 조성물.A pharmaceutical composition for the prevention or treatment of allergies comprising rose extract as an active ingredient.
  8. 제7항에 있어서, 상기 알레르기는 급성 알레르기에 의해 유발되는 전신성 쇼크반응 또는 피부 가려움증인, 알레르기의 예방 또는 치료용 약학적 조성물.The pharmaceutical composition for preventing or treating allergies according to claim 7, wherein the allergy is a systemic shock reaction or skin itching caused by an acute allergy.
  9. 장미 추출물을 유효성분으로 포함하는 알레르기의 예방 또는 개선용 건강기능식품.Health functional food for the prevention or improvement of allergies containing rose extract as an active ingredient.
  10. 장미 추출물을 개체에 투여하는 단계를 포함하는 비만의 예방, 개선 또는 치료방법.A method for preventing, improving or treating obesity, comprising administering a rose extract to an individual.
  11. 비만의 예방 또는 치료를 위한 약제의 제조에 사용하기 위한 장미 추출물의 용도.Use of rose extract for use in the manufacture of a medicament for the prevention or treatment of obesity.
  12. 장미 추출물을 개체에 투여하는 단계를 포함하는 알레르기의 예방, 개선 또는 치료방법.A method of preventing, improving or treating allergies comprising administering rose extract to an individual.
  13. 알레르기의 예방 또는 치료를 위한 약제의 제조에 사용하기 위한 장미 추출물의 용도.Use of rose extract for use in the manufacture of a medicament for the prevention or treatment of allergies.
PCT/KR2020/014909 2019-11-08 2020-10-29 Phamaceutical composition for preventing or treating obesity or allergy comprising rose extract as active ingredient WO2021091164A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0142578 2019-11-08
KR1020190142578A KR102281387B1 (en) 2019-11-08 2019-11-08 Phamaceutical composition for preventing or treating of obesity or allergy comprising rose extract as an active ingredient

Publications (1)

Publication Number Publication Date
WO2021091164A1 true WO2021091164A1 (en) 2021-05-14

Family

ID=75848471

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/014909 WO2021091164A1 (en) 2019-11-08 2020-10-29 Phamaceutical composition for preventing or treating obesity or allergy comprising rose extract as active ingredient

Country Status (2)

Country Link
KR (2) KR102281387B1 (en)
WO (1) WO2021091164A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022250356A1 (en) * 2021-05-25 2022-12-01 주식회사 디자인셀 Pharmaceutical composition for preventing or treating allergic diseases containing rose extract as active ingredient
KR102696677B1 (en) * 2021-12-29 2024-08-21 주식회사 유한건강생활 A composition for improving, preventing and treating of obesity metabolic disease comprising Rosa multiflora root extract

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140073722A (en) * 2012-12-06 2014-06-17 한국식품연구원 Composition for preventing, improving or treating of th2-mediated immune disease comprising extracts from rosa multiflora as an active ingredients
KR20150000977A (en) * 2013-06-26 2015-01-06 (주)아모레퍼시픽 Composition containing rose extract
KR20190023962A (en) * 2017-08-30 2019-03-08 한국식품연구원 Composition for Preventing, Improving or Treating Immune Disease Comprising Fraction of Rosa multiflora extract as an Active Ingredients

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102119368B1 (en) 2018-04-24 2020-06-08 경북대학교 산학협력단 Pharmaceutical Composition comprising Elaeocarpusin for Preventing or Treating of Mast Cell mediated Allergic Disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140073722A (en) * 2012-12-06 2014-06-17 한국식품연구원 Composition for preventing, improving or treating of th2-mediated immune disease comprising extracts from rosa multiflora as an active ingredients
KR20150000977A (en) * 2013-06-26 2015-01-06 (주)아모레퍼시픽 Composition containing rose extract
KR20190023962A (en) * 2017-08-30 2019-03-08 한국식품연구원 Composition for Preventing, Improving or Treating Immune Disease Comprising Fraction of Rosa multiflora extract as an Active Ingredients

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOI, JEONG-HWA;BAEK, JI-YUN;CHOI, HEE-JIN;: "Effects of Rosa multiflora and Rosa multiflora Complex on Lipid Content in Rats Fed a High-Fat¡¤High-Cholesterol Diet", JOURNAL OF THE KOREAN SOCIETY OF FOOD SCIENCE AND NUTRITION, KOREAN INTELLECTUAL PROPERTY OFFICE, vol. 44, no. 6, 30 June 2015 (2015-06-30), pages 791 - 799, XP053034101, ISSN: 1226-3311 *
ZHANG, G.Q. ; HUANG, X.D. ; WANG, H. ; LEUNG, A.K.N. ; CHAN, C.L. ; FONG, D.W.F. ; YU, Z.L.: "Anti-inflammatory and analgesic effects of the ethanol extract of Rosa multiflora Thunb. hips", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER IRELAND LTD, IE, vol. 118, no. 2, 23 July 2008 (2008-07-23), IE, pages 290 - 294, XP022758520, ISSN: 0378-8741, DOI: 10.1016/j.jep.2008.04.014 *

Also Published As

Publication number Publication date
KR20210056025A (en) 2021-05-18
KR20210056289A (en) 2021-05-18
KR102281388B1 (en) 2021-07-26
KR102281387B1 (en) 2021-07-26

Similar Documents

Publication Publication Date Title
WO2010104309A2 (en) Compositions for preventing or improving gastrointestinal diseases
WO2020246777A1 (en) Method for preparing iridoid-rich noni fruit extract or fraction thereof, method for preparing immune-enhancing active material-rich noni fruit extract or fraction thereof and use of noni fruit extract or fraction thereof
WO2021091164A1 (en) Phamaceutical composition for preventing or treating obesity or allergy comprising rose extract as active ingredient
WO2015002391A1 (en) Composition having a function for alleviating premenstrual syndrome and menstrual pain
WO2018208128A1 (en) Pharmaceutical composition containing tilianin as active ingredient for prevention or treatment of parkinson's disease
WO2018080156A1 (en) Composition for preventing, improving or treating cognitive impairment, containing potentilla fragarioides extract as active ingredient
WO2021033994A1 (en) Composition comprising salvia miltiorrhiza or paeonia lactiflora extract as active ingredient for prevention or treatment of lipid metabolism disorder
WO2022045418A1 (en) Health functional food, comprising siberian chrysanthemum extract, for pain relief or antioxidation
WO2020256464A1 (en) Use of fraction of apios americana tuber extract having anti-inflammatory activity as preventive or therapeutic agent for alcoholic gastritis, and production method thereof
WO2017159912A1 (en) Antidiabetic functional composition containing hot water extract of ramulus mori and oxyresveratrol as active ingredients and method for producing thereof
WO2022182199A1 (en) Composition containing hot water extract of blackcurrant for preventing, alleviating, or treating non-alcoholic fatty liver diseases
WO2012105816A2 (en) Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof
WO2022220458A1 (en) Composition including aurantii fructus immaturus extract as active ingredient for prevention or treatment of male climacteric symptom
WO2022211396A1 (en) Pharmaceutical composition including salvia plebeia r. br. extract or compound derived therefrom as active ingredient for prevention or treatment of muscular dystrophy
WO2022055218A1 (en) Composition for preventing or treating hair loss, comprising extract of corydalis yanhusuo
WO2021071321A1 (en) Composition for preventing or treating neurodegenerative diseases containing mixed herbal extract of genkwae flos, clematidis radix, and gastrodiae rhizoma
WO2022250356A1 (en) Pharmaceutical composition for preventing or treating allergic diseases containing rose extract as active ingredient
WO2021091356A1 (en) Composition for preventing or treating stress-related diseases including methyl benzoate as active ingredient
WO2018190638A1 (en) Composition for preventing or treating corneal diseases, containing glycine max extract
WO2024122768A1 (en) Composition for preventing or ameliorating insomnia, comprising poria cocos extract
WO2023191249A1 (en) Composition for ameliorating obesity or lipid metabolism comprising asimina triloba extract
WO2019151547A1 (en) Composition for preventing, improving or treating degenerative neurological disease comprising fraction of a quilaria agallocha roxburgh extract as active ingredient
WO2018080158A1 (en) Composition for preventing, improving or treating cognitive impairment, containing elaeagnus glabra extract as active ingredient
WO2021242044A1 (en) Composition comprising hibiscus, rosemary, and grape seed extract as active ingredient for preventing or treating degenerative brain disease
WO2010016675A2 (en) Pharmaceutical composition for preventing and treating inflammatory diseases containing extracts of the immature fruit of rhus succedanea as active ingredients

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20884438

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20884438

Country of ref document: EP

Kind code of ref document: A1